Bayer Posts Strong Q1 Earnings as €1 Billion Crop Science Efficiency Plan and $2.45 Billion Pharma Deal Battle Legal Cash Burn

Bayer posts strong Q1 operational results with core EPS up, but €2.3B free cash outflow from glyphosate and PCB litigation weighs; guidance raised for 2026.

Bayer turned in a solid first quarter on the operating front, with core earnings per share jumping to €2.71 from €2.40 a year earlier. But behind those numbers lies a company wrestling with a €2.3 billion free cash outflow in the period, driven almost entirely by legal payments tied to PCB and glyphosate litigation. The contrast neatly captures the dual reality of the German life-science group: operational momentum is building, yet the financial headwinds from its long-running legal saga show no sign of easing.

The quarter marked the first set of results under incoming CFO Judith Hartmann, who joined the board on March 1 and will formally take the finance reins when Wolfgang Nickl departs at the end of May. Group revenue rose to €13.4 billion, a currency- and portfolio-adjusted increase of 4.1%, while EBITDA before special items climbed 9% to €4.5 billion — a figure that absorbed currency headwinds of nearly €900 million. Net income more than doubled to €2.8 billion. Yet the cash picture was stark: €2.0 billion flowed out for PCB and glyphosate settlements, pushing net financial debt to €32.5 billion, up 9% from the end of 2025.

Management responded by nudging up its full-year guidance. The revenue range now stands at €44.5 billion to €46.5 billion, with adjusted EBITDA targeted at €9.4 billion to €9.9 billion. Free cash flow for 2026, however, remains stuck at minus €2.5 billion to minus €1.5 billion, a number that already incorporates roughly €5 billion in litigation-related outflows.

Crop Science Efficiency Drive Takes Centre Stage

Within agriculture, Bayer reaffirmed its five-year plan for the Crop Science division, pledging to cut more than €1 billion in costs over that horizon while adding €3.5 billion in annual revenue. The core sales growth target sits at 1% to 4% per year. The strategy hinges on a mix of cost discipline and a robust product pipeline — including Preceon corn, Vyconic soybeans, Bollgard 4 and the herbicide Icafolin — to push the operating margin from 19.4% toward a medium-term target of 20% to 22%. The first quarter provided early evidence that efficiency measures are gaining traction, with Crop Science acting as the primary driver behind the earnings improvement.

Pharma Pipeline Gets a $2.45 Billion Injection

Alongside the agricultural push, Bayer is expanding its pharmaceuticals segment with the acquisition of Perfuse Therapeutics, a deal valued at up to $2.45 billion. The upfront payment is $300 million, with the remainder contingent on milestones. The centrepiece of the transaction is PER-001, a Phase II candidate for glaucoma and diabetic retinopathy — a field where Bayer already has a presence through Eylea. The acquisition is Bayer’s first significant biopharma deal since the Vividion Therapeutics purchase in 2021. Separately, the company announced positive Phase III data for a PET/CT radiotracer targeting cardiac amyloidosis, with plans to discuss a filing with the FDA.

Stock Shows Gains but Remains Far from Its Peak

The shares closed at €38.26 recently, about 22% below the 52-week high of €49.17 struck in February. Over the past 12 months, the stock has still climbed 72%, reflecting a broader recovery from the depths of the litigation overhang. On a shorter horizon, the seven-day performance shows a 3% gain, but the 30-day reading remains negative at minus 6.5%. Year-to-date, the price is essentially flat. Technical indicators paint a mixed picture: the relative strength index at 67.5 suggests the recent rally is advanced, though the stock sits well above its 200-day moving average.

The Legal Calendar Looms Large

The biggest unknown remains the glyphosate litigation. A key deadline arrives in early June, when claimants in the class-action settlement must decide whether to accept the terms. By the end of June, the U.S. Supreme Court is expected to rule on a separate appeal that could reshape Bayer’s legal exposure. Should the company manage to largely close the glyphosate chapter, the path to swift debt reduction would open — and Hartmann’s tenure as CFO would begin on far firmer footing. For now, the market is watching whether Crop Science can deliver the margin improvement outlined in the five-year plan, while the legal clock ticks toward two critical junctures.